These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25875381)

  • 1. Histone deacetylases and atherosclerosis.
    Zheng XX; Zhou T; Wang XA; Tong XH; Ding JW
    Atherosclerosis; 2015 Jun; 240(2):355-66. PubMed ID: 25875381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone Deacetylase 9 Activates IKK to Regulate Atherosclerotic Plaque Vulnerability.
    Asare Y; Campbell-James TA; Bokov Y; Yu LL; Prestel M; El Bounkari O; Roth S; Megens RTA; Straub T; Thomas K; Yan G; Schneider M; Ziesch N; Tiedt S; Silvestre-Roig C; Braster Q; Huang Y; Schneider M; Malik R; Haffner C; Liesz A; Soehnlein O; Bernhagen J; Dichgans M
    Circ Res; 2020 Aug; 127(6):811-823. PubMed ID: 32546048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research Progress on Histone Deacetylases Regulating Programmed Cell Death in Atherosclerosis.
    Zhou G; Liu Y; Wu H; Zhang D; Yang Q; Li Y
    J Cardiovasc Transl Res; 2024 Apr; 17(2):308-321. PubMed ID: 37821683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of histone deacetylases in vascular cell homeostasis and arteriosclerosis.
    Zhou B; Margariti A; Zeng L; Xu Q
    Cardiovasc Res; 2011 Jun; 90(3):413-20. PubMed ID: 21233251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The important role of histone deacetylases in modulating vascular physiology and arteriosclerosis.
    Zhao TC; Wang Z; Zhao TY
    Atherosclerosis; 2020 Jun; 303():36-42. PubMed ID: 32535412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases.
    Eom GH; Kook H
    Pharmacol Ther; 2014 Aug; 143(2):168-80. PubMed ID: 24594235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rho-GTPase and Atherosclerosis: Pleiotropic Effects of Statins.
    Cai A; Zhou Y; Li L
    J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26124206
    [No Abstract]   [Full Text] [Related]  

  • 8. Histone deacetylase 9 promotes endothelial-mesenchymal transition and an unfavorable atherosclerotic plaque phenotype.
    Lecce L; Xu Y; V'Gangula B; Chandel N; Pothula V; Caudrillier A; Santini MP; d'Escamard V; Ceholski DK; Gorski PA; Ma L; Koplev S; Bjørklund MM; Björkegren JL; Boehm M; Bentzon JF; Fuster V; Kim HW; Weintraub NL; Baker AH; Bernstein E; Kovacic JC
    J Clin Invest; 2021 Aug; 131(15):. PubMed ID: 34338228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review.
    Chen X; He Y; Fu W; Sahebkar A; Tan Y; Xu S; Li H
    Front Cell Dev Biol; 2020; 8():581015. PubMed ID: 33282862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The regulatory role of DPP4 in atherosclerotic disease.
    Duan L; Rao X; Xia C; Rajagopalan S; Zhong J
    Cardiovasc Diabetol; 2017 Jun; 16(1):76. PubMed ID: 28619058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetics in vascular disease - therapeutic potential of new agents.
    Xu SS; Alam S; Margariti A
    Curr Vasc Pharmacol; 2014 Jan; 12(1):77-86. PubMed ID: 22724461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting epigenetic enzymes to improve atherogenic macrophage functions.
    Van den Bossche J; Neele AE; Hoeksema MA; de Heij F; Boshuizen MC; van der Velden S; de Boer VC; Reedquist KA; de Winther MP
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):396-402. PubMed ID: 25446073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylases as regulators of inflammation and immunity.
    Shakespear MR; Halili MA; Irvine KM; Fairlie DP; Sweet MJ
    Trends Immunol; 2011 Jul; 32(7):335-43. PubMed ID: 21570914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biology and therapeutic implications of HDACs in the heart.
    McKinsey TA
    Handb Exp Pharmacol; 2011; 206():57-78. PubMed ID: 21879446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting histone deacetylases: A novel therapeutic strategy for atrial fibrillation.
    Lkhagva B; Kao YH; Chen YC; Chao TF; Chen SA; Chen YJ
    Eur J Pharmacol; 2016 Jun; 781():250-7. PubMed ID: 27089819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological strategies to inhibit intra-plaque angiogenesis in atherosclerosis.
    Perrotta P; Emini Veseli B; Van der Veken B; Roth L; Martinet W; De Meyer GRY
    Vascul Pharmacol; 2019 Jan; 112():72-78. PubMed ID: 29933080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural products as zinc-dependent histone deacetylase inhibitors.
    Tan S; Liu ZP
    ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombosis formation on atherosclerotic lesions and plaque rupture.
    Badimon L; Vilahur G
    J Intern Med; 2014 Dec; 276(6):618-32. PubMed ID: 25156650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elastin fragmentation and atherosclerosis progression: the elastokine concept.
    Maurice P; Blaise S; Gayral S; Debelle L; Laffargue M; Hornebeck W; Duca L
    Trends Cardiovasc Med; 2013 Aug; 23(6):211-21. PubMed ID: 23561795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors in the treatment of lymphoma.
    Lemoine M; Younes A
    Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.